Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis

Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis

<p><strong>Objective:</strong> Assess pooled safety results through the end of the Phase 2/3 studies of guselkumab (≤2 years) in tumor necrosis factor-α inhibitor (TNFi) -naïve and -experienced patients with psoriatic arthritis (PsA).</p> <p><strong>Methods:<...

Descripció completa

Dades bibliogràfiques
Autors principals:	Rahman, P, Boehncke, W-H, Mease, PJ, Gottlieb, AB, McInnes, IB, Shawi, M, Wang, Y, Sheng, S, Kollmeier, AP, Theander, E, Yu, J, Leibowitz, E, Marrache, AM, Coates, LC
Format:	Journal article
Idioma:	English
Publicat:	Journal of Rheumatology 2023

Ítems similars

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
per: Coates, LC, et al.
Publicat: (2024)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria
per: Ritchlin, CT, et al.
Publicat: (2023)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
per: Coates, LC, et al.
Publicat: (2024)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
per: Coates, L, et al.
Publicat: (2022)

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free
per: Coates, LC, et al.
Publicat: (2021)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
per: Coates, L, et al.
Publicat: (2021)

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
per: Siebert, S, et al.
Publicat: (2024)

Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis
per: Siebert, S, et al.
Publicat: (2024)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
per: Joseph F Merola, et al.
Publicat: (2022-03-01)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
per: Orbai, A-M, et al.
Publicat: (2019)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
per: Dennis McGonagle, et al.
Publicat: (2023-04-01)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
per: Laura C. Coates, et al.
Publicat: (2024-02-01)

Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
per: Jeffrey R. Curtis, et al.
Publicat: (2024-02-01)

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
per: Philip J Mease, et al.
Publicat: (2023-02-01)

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
per: Iain B McInnes, et al.
Publicat: (2024-12-01)

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
per: Christopher T. Ritchlin, et al.
Publicat: (2023-03-01)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
per: Christopher T. Ritchlin, et al.
Publicat: (2023-01-01)

Meaningful improvement in general health outcomes with Guselkumab treatment for psoriatic arthritis: Patient-Reported Outcomes Measurement Information System-29 results from a phase 3 study
per: Orbai, A-M, et al.
Publicat: (2022)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
per: Laure Gossec, et al.
Publicat: (2024-02-01)

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
per: Richard B. Warren, et al.
Publicat: (2024-03-01)

Guselkumab: widened action in psoriatic disease
per: Marcelo Arnone, et al.
Publicat: (2021-05-01)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
per: Yang Chen, et al.
Publicat: (2022-03-01)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
per: Philip J. Mease, et al.
Publicat: (2023-10-01)

Measuring outcomes in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2020)

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
per: Merola, JF, et al.
Publicat: (2022)

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
per: Proton Rahman, et al.
Publicat: (2021-07-01)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
per: Fabrizio Martora, MD, et al.
Publicat: (2023-11-01)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
per: Reem Kashlan, MPH, et al.
Publicat: (2021-04-01)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
per: Ana-Maria Orbai, et al.
Publicat: (2023-09-01)

Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study
per: Philip J. Mease, et al.
Publicat: (2024-12-01)

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
per: Coates, LC, et al.
Publicat: (2024)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
per: Coates, L, et al.
Publicat: (2019)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2023)

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
per: Atul Deodhar, et al.
Publicat: (2021-04-01)

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
per: McInnes, IB, et al.
Publicat: (2023)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
per: Peter Nash, et al.
Publicat: (2020-09-01)

Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies
per: Mease, PJ, et al.
Publicat: (2024)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study
per: Ritchlin, CT, et al.
Publicat: (2023)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
per: Dafna D. Gladman, et al.
Publicat: (2022-09-01)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
per: Gladman, DD, et al.
Publicat: (2018)